Psychedelic Alpha published a Psychedelic Alpha Bulletin featuring developments on psychedelic drug development, policy, and access, including the shuttering of an at-home ketamine company and Carey Turnbull pivoting to pursuing polymorph patents.
Public source
Publisher name
Public post
Our latest Psychedelic Alpha Bulletin catches you up on various developments from around the worlds of psychedelic drug development, policy, and access. Featured stories…
Company
Psychedelic Alpha
The leading independent, data-driven voice in psychedelics.
- Industry
- Business Consulting and Services
- Location
- London, GB
- Company size
- 2–10 employees
About Psychedelic Alpha
The definitive resource for analysis of the emergent psychedelic medicine sector. Cut through the noise with exclusive news, interviews, data and opportunities.
See moreLatest activity
Latest activity from Psychedelic Alpha
13 signals
Strategy & Corporate Development
Psychedelic Alpha completed the acquisition of Psychedelic Drug Developer AtaiBeckley by Eli Lilly and Company for a total value of up to $3.8 billion.
Research & Knowledge
Psychedelic Alpha published an overview entry exploring anticipating psychedelic REMS programs, further considerations, shared REMS, REMS as competitive strategy, impact on patient access, off-label use, and drug scheduling.
Research & Knowledge
Psychedelic Alpha published a research paper by Dr. Edward Jacobs and Dr. Bryony Insua-Summerhays in The Ethics Corner for The Psychedelic Practitioner's Special Issue on Preparedness.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Multidisciplinary Association for Psychedelic Studies (MAPS)
Multidisciplinary Association for Psychedelic Studies (MAPS) published a new JAMA Network Open study highlighting a gap in how safety is currently monitored within Oregon’s regulated psilocybin program.
Research & Knowledge
DELPHI
DELPHI expanded the literature on Blossom, including a broader full catalogue of psychedelic research covering research across psychedelics including MDMA and ketamine.
Research & Knowledge
Pacific Mind Health
Pacific Mind Health published a blog post titled Is Ketamine Addictive? Understanding the Real Risks, which discusses two recent systematic reviews finding minimal evidence of craving, dose escalation, or misuse when ketamine was administered at therapeutic doses under clinical supervision.
Research & Knowledge
Psychedelic Support
Psychedelic Support is recruiting participants for a study on psych*edel experiences and attitudes toward death in adults aged 40 and over, involving a 25-30 minute anonymous online survey and UCL Research Ethics Committee approval.
Research & Knowledge
States of Mind